Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Eur J Med Chem ; 145: 559-569, 2018 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-29339251

RESUMEN

Enteroviruses are among the most common and important human pathogens for which there are no specific antiviral agents approved by the US Food and Drug Administration so far. Particularly, coxsackievirus infections have a worldwide distribution and can cause many important diseases. We here report the synthesis of new 14 quinoxaline derivatives and the evaluation of their cytotoxicity and antiviral activity against representatives of ssRNA, dsRNA and dsDNA viruses. Promisingly, three compounds showed a very potent and selective antiviral activity against coxsackievirus B5, with EC50 in the sub-micromolar range (0.3-0.06 µM). A combination of experimental techniques (i.e. virucidal activity, time of drug addition and adsorption assays) and in silico modeling studies were further performed, aiming to understand the mode of action of the most active, selective and not cytotoxic compound, the ethyl 4-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]benzoate (6).


Asunto(s)
Antivirales/farmacología , Enterovirus Humano B/efectos de los fármacos , Quinoxalinas/farmacología , Animales , Antivirales/síntesis química , Antivirales/química , Bovinos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Cricetinae , Relación Dosis-Respuesta a Droga , Haplorrinos , Humanos , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Estructura Molecular , Quinoxalinas/síntesis química , Quinoxalinas/química , Relación Estructura-Actividad
2.
Eur J Med Chem ; 41(9): 1102-7, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16828932

RESUMEN

Fifteen imidazo[1,2-a] and [1,2,4]triazolo[4,3-a]quinoxalines were prepared. These compounds bear at position 4 various substituents related to the moieties present in classical and non-classical antifolic agents. And we evaluated in vitro antimicrobial, antiviral and antiproliferative activities. In particular, title compounds were evaluated in vitro against representative strains of Gram-positive and Gram-negative bacteria (S. aureus, Salmonella spp.), mycobacteria (M. fortuitum, M. smegmatis ATCC 19420 and M. tuberculosis ATCC 27294), yeast and moulds (C. albicans ATCC 10231 and A. fumigatus). Furthermore, their antiretroviral activity against HIV-1 was determined in MT-4 cells together with cytotoxicity. In these assays title compounds were tested for their capability to prevent MT-4 cell growth. Among the examined series, the compounds 5, 7 and 10 showed cytotoxicity against mock-infected MT-4 cells.


Asunto(s)
Imidazoles/química , Quinoxalinas/química , Quinoxalinas/toxicidad , Triazoles/química , Línea Celular , Proliferación Celular/efectos de los fármacos , Humanos , Estructura Molecular , Quinoxalinas/síntesis química , Relación Estructura-Actividad
3.
Eur J Med Chem ; 53: 83-97, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22513121

RESUMEN

Within a project aimed at discovering new Flaviviridae inhibitors, new variously substituted 2-phenylbenzimidazoles were synthesized and evaluated in cell-based assays for cytotoxicity and antiviral activity against viruses representatives of the three genera of the Flaviviridae family, i.e.: Pestivirus (BVDV), Flavivirus (YFV) and Hepacivirus (HCV). Title compounds were also tested against RNA viruses representative of other single-stranded, positive-sense (ssRNA(+)) negative-sense (RNA(-)), or double-stranded (dsRNA) genomes, as well as against representatives of two DNA virus families. Nine compounds showed activity against BVDV (EC(50) = 0.8-8.0 µM), compound 31 being the most potent (EC(50) = 0.80 µM) and selective (SI = CC(50)/EC(50) = >100). When tested in an HCV replicon assay, compound 31 resulted again the most potent, displaying an EC(50) value of 1.11 µM and an SI of 100. Besides inhibiting BVDV, two compounds (35 and 38) showed a moderate activity also against YFV (EC(50) = 13 µM). Interestingly, 35 was moderately active also against RSV (EC(50) = 25 µM).


Asunto(s)
Antivirales/química , Antivirales/farmacología , Bencimidazoles/química , Bencimidazoles/farmacología , Virus/efectos de los fármacos , Animales , Antivirales/síntesis química , Antivirales/toxicidad , Bencimidazoles/síntesis química , Bencimidazoles/toxicidad , Bovinos , Línea Celular , Cricetinae , Diseño de Fármacos
4.
Med Chem ; 6(2): 70-8, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20470249

RESUMEN

As a follow up of an anti-Flaviviridae project, a new series of variously substituted 2-styryl-benzimidazoles were synthesized and tested in vitro for biological activity. Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Pestiviruses and Flaviviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae) as well as for cytotoxicity tests, run in parallel with antiviral assays,against MDBK, BHK and Vero 76 cells. In the series examined, new leads emerged against BVDV, CVB-2 and RSV. Compounds 11, 12, 17, 18, 24, 31 exhibited anti-BVDV activity in the concentration range 1.7-16 microM; among them, compound 17 was the most active, with an EC(50) = 1.7 microM. Compounds 18 and 21 were equally active against CVB-2, with EC(50) values of 7 - 8 microM, while the derivative 30 was active against RSV with EC(50)= 1 microM and represents a new lead compound.


Asunto(s)
Antivirales/síntesis química , Antivirales/farmacología , Bencimidazoles/síntesis química , Bencimidazoles/farmacología , Virus ADN/efectos de los fármacos , Flaviviridae/efectos de los fármacos , Virus ARN/efectos de los fármacos , Estirenos/síntesis química , Estirenos/farmacología , Animales , Antivirales/química , Bencimidazoles/química , Bovinos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Chlorocebus aethiops , Cricetinae , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Pruebas de Sensibilidad Microbiana , Conformación Molecular , Estereoisomerismo , Relación Estructura-Actividad , Estirenos/química , Células Vero
5.
Eur J Med Chem ; 44(4): 1579-91, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18774202

RESUMEN

A series of novel 5,7-diamino-3-phenyl-2-benzylamino, 2-phenoxy, and 2-thiophenyl substituted quinoxalines has been designed, synthesized and evaluated for their in vitro antitumor activity towards cell lines of nine different types of human cancers. Some of these compounds exhibited inhibitory effects on the growth of a wide range of cancer cell lines generally at 10(-6) M, in some cases at 10(-7) M and 10(-8) M concentrations. Within this series the benzylamino quinoxaline derivatives 1b-7b were the most active, whereas compound 2c showed the highest MG_MD value (-5.66).


Asunto(s)
Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Diseño de Fármacos , Quinoxalinas/síntesis química , Quinoxalinas/farmacología , Antineoplásicos/química , Línea Celular Tumoral , Humanos , Quinoxalinas/química
6.
Med Chem ; 5(6): 507-16, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19534676

RESUMEN

In prosecution of an anti-Flaviviridae project a new series of variously substituted 2-diphenyl-benzimidazoles were synthesized and tested in vitro for antiviral and antiproliferative activities. Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Flaviviruses and Pestiviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae). The 5-Acetyl-2-(4'-nitrobiphenyl-4-yl)-1H-benzimidazole (24) emerged as potent active lead compound against Yellow Fever Virus (a Flavivirus) (EC(50) = 0.5 microM) and CVB-2 at 1 microM and was not cytotoxic, whereas the other title benzimidazoles showed no antiviral activity at concentrations not cytotoxic for the resting cell monolayers. Among the examined series, the most cytotoxic derivatives (11,12,14,16,18,19,20,21,23,25-30) against mock-infected MT-4 cells (CC50 < 8.0 microM) were evaluated against a panel of human cell lines derived from haematological and solid tumours,using 6-mercaptopurine (6-MP) and etoposide as reference drugs. In particular, compounds 26 and 28 showed a similar potency of 6-MP and etoposide.


Asunto(s)
Antivirales/química , Antivirales/farmacología , Bencimidazoles/química , Bencimidazoles/farmacología , Proliferación Celular/efectos de los fármacos , Animales , Antivirales/toxicidad , Bencimidazoles/toxicidad , Línea Celular Tumoral , Flaviviridae/efectos de los fármacos , Humanos
7.
Eur J Pharmacol ; 615(1-3): 17-26, 2009 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-19446547

RESUMEN

The cytotoxicity of two novel folate cycle inhibitors with quinoxalinic structure, 3-methyl-7-trifluoromethyl-2(R)-[3,4,5-trimethoxyanilino]-quinoxaline (453R) and 3-piperazinilmethyl-2[4(oxymethyl)-phenoxy]quinoxaline (311S), was tested against a panel of both cisplatin(cDDP)-sensitive and -resistant carcinoma cell lines. Interestingly, the cisplatin-resistant human ovarian line, C13 cells, exhibited collateral sensitivity towards the two compounds when compared to its sensitive parental 2008 cells. In this resistant line, which showed elevated expression of the folate cycle enzymes, thymidylate synthase (TS) and dihydrofolate reductase (DHFR), due to cisplatin-resistance phenotype, collateral sensitivity correlated with the greater reduction of enzyme expression. In addition, TS and DHFR expression of the other resistant lines, the human ovarian carcinoma A2780/CP cells and the human breast cancer MDA/CH cells, were decreased in accordance with the similar sensitivity or the low level of cross-resistance to these compounds in comparison to their respective parental lines. Noteworthy, unlike 5-fluorouracil, both drugs reduced the level of TS without inducing ternary complex formation with the co-substrate and the nucleotide analogue. Median effect analysis of the interactive effects of cisplatin with the two quinoxalines mainly showed additive or synergistic cell killing, depending on schedules of drug combinations. In particular, synergistic effects were more often obtained, even on the resistant cells, when cisplatin was added at the beginning of the treatment. These results indicate that, despite the possibility of other mechanisms being involved, inhibition of TS cycle enzymes plays an important role in the pharmacology of these compounds, which might also represent a useful component in drug treatment protocols against cDDP-resistant cells.


Asunto(s)
Cisplatino/farmacología , Antagonistas del Ácido Fólico/farmacología , Tetrahidrofolato Deshidrogenasa/biosíntesis , Timidilato Sintasa/antagonistas & inhibidores , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cistadenocarcinoma Seroso , Resistencia a Antineoplásicos , Femenino , Fluorouracilo/farmacología , Humanos , Neoplasias Ováricas , Quinoxalinas/farmacología , Tetrahidrofolato Deshidrogenasa/genética , Timidilato Sintasa/biosíntesis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA